$OSUR

OraSure Technologies (OSUR) reached an agreement with activist investor Altai Capital, avoiding a proxy battle. Altai, holding a 5.2% stake, had pushed for strategic changes and a potential sale. The deal includes Altai withdrawing its board nominations and agreeing to ownership limits. OSUR shares rose about 10% since February.

OraSure Technologies (OSUR) reported a Q3 loss of $13.1M, or 19 cents per share. Adjusted losses were 15 cents per share. Revenue was $30.9M. The company expects Q4 revenue between $30M and $32M.

ORASURE TECHNOLOGIES INC (OSUR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Investor Contact: Media Contact: Mike Vallie Amy Koch investorinfo@orasure.com media@orasure.com OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion • 14% year-over-year revenue gr

OraSure (OSUR) reported Q2 2026 GAAP net income of $6.2M, reversing a $19.7M loss from a year earlier. Revenue rose 9.7% quarter-over-quarter to $30.6M, beating guidance. Gross margins improved, and diagnostics revenue grew 1% YoY. The profit was largely due to a $22.6M accounting adjustment, with underlying losses widening. The company secured two FDA clearances but delayed a product submission. Hedge fund ownership increased, and short interest is 4.79%.

OraSure Technologies (OSUR) reported Q2 2026 revenue of $30.6M, up 9.7% sequentially, including $19.4M Diagnostics revenue and $9.9M Sample Management Solutions revenue. GAAP gross margin was 43.5% and GAAP operating income $5.4M. Q3 revenue guidance is $29.5M to $32.5M. Management said FDA clearance for Colli-Pee and EUA for OraQuick Ebola 2.0 were received, while IntelliQ CT/NG submission was withdrawn.

ORASURE TECHNOLOGIES INC (OSUR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Investor Contact: Media Contact: investorinfo@orasure.com media@orasure.com OraSure Announces Second Quarter 2026 Financial Results BETHLEHEM, PA, August 5, 2026 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnost

OraSure Technologies said the U.S. FDA granted Emergency Use Authorization for its second generation OraQuick Ebola 2.0 Rapid Antigen Test. The single-use test detects four Ebola virus types and can use blood or oral fluids. OraSure cited improved sensitivity, longer shelf life, and automated manufacturing, and plans to ramp production. The DRC and Uganda outbreak has 2,473 cases and 999 deaths, per Congo’s Ministry of Health.

OraSure (NASDAQ: OSUR) said the FDA has cleared its Colli-Pee at-home urine collection kit, made by subsidiary DNA Genotek, for use with Roche molecular diagnostic systems to identify multiple STIs. OraSure called the clearance important for future growth and noted it also filed for a rapid molecular self-test for Chlamydia and gonorrhoeae. Shares were up over 2% to $4.14.

OraSure Technologies said the FDA cleared its Colli-Pee™•Dx urine collection kit (from subsidiary DNA Genotek) for at-home first-void urine collection for Roche cobas 5800/6800/8800 molecular testing. The kit supports tests for Chlamydia, Gonorrhea, Trichomonas vaginalis, and Mycoplasma genitalium, enabling mail-in workflows and decentralized STI screening.

Peapod Lane Capital LLC significantly increased its stake in OraSure Technologies, making it their 17th-largest holding. Meanwhile, insider activity shows the CEO and CFO recently purchased shares, indicating confidence in the company. Despite this, OraSure Technologies is currently trading near $3.05 with a "Reduce" analyst consensus and a target price of $3.00, having reported negative EPS and margins last quarter.